Sanofi-aventis has reported that Multaq (dronedarone) 400mg tablets, for atrial fibrillation or atrial flutter, is now available in the US.
Multaq is an anti-arrhythmic drug indicated to reduce the risk of cardiovascular hospitalization in patients with paroxysmal or persistent atrial fibrillation (AF) or atrial flutter (AFL).
To ensure the use of Multaq in the appropriate patient population, the company has launched mPACT, the Risk Evaluation and Mitigation Strategy (REMS).
The mPACT Partnership was developed to assist healthcare professionals with the identification of appropriate patients and to ensure the safe use of Multaq while minimizing risk.
Gerald Naccarelli, chief, Division of Cardiology, Pennsylvania State University College of Medicine, said: “Multaq may help patients with atrial fibrillation or atrial flutter stay out of the hospital, which is an important factor in treatment that is often not addressed. We welcome a new option that may help patients with Afib or Aflutter manage their disease.”